Phase I/II trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance.

Trial Profile

Phase I/II trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs SCIB 2 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2017 According to a Scancell media release, under the terms of the Clinical Development Partnership, Cancer Research UK will fund and sponsor this trial.
    • 01 Feb 2017 New trial record
    • 30 Jan 2017 According to a Scancell Holdings PLC media release, this trial is expected to start in 2018 and complete approximately 18 months later.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top